IMMX Immix Biopharma
- 2.435
- +0.125+5.41%
Immix Biopharma News
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment
Immix Biopharma (IMMX) said Monday that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma. The designation qualifies NXC-201 among others for
Express News | Immix Biopharma Awarded European Union Orphan Drug Designation for Nxc-201 in Multiple Myeloma
Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation v
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No
Express News | Immix Biopharma Announces Late-Breaking Nxc-201 Clinical Data Abstract Accepted for Oral Presentation at the 27TH Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)
Express News | Immix Biopharma Announces Comprehensive Cancer Center As Lead Site For NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder le
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and
Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In AL Amyloidosis
European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol
Immix Biopharma Announces New Offering, Sparks Investor Interest
Immix Biopharma Signs Definitive $15M Titan Partnership Deal
PRSO, AKRO and MIRA Among Pre-market Losers
Immix Biopharma Suspends Stock Offering Pending New Prospectus
Immix Biopharma Prices $15 Million Stock Offering
Immix Biopharma (IMMX) said late Monday it priced an underwritten public offering of approximately 5.5 million shares of common stock at $2.71 per share for expected gross proceeds of $15 million. The
Immix Is a Clinical-Stage Biopharmaceutical Co Developing Cell Therapies in Autoimmune Disease >IMMX
Immix Is a Clinical-Stage Biopharmaceutical Co Developing Cell Therapies in Autoimmune Disease >IMMX
Immix Biopharma: Titan Partners Group, a Division of American Capital Partners, Is Sole Bookrunning Manager for Offering >IMMX
Immix Biopharma: Titan Partners Group, a Division of American Capital Partners, Is Sole Bookrunning Manager for Offering >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Expects Gross Proceeds of About $15M From Offering >IMMX
Immix Biopharma Expects Gross Proceeds of About $15M From Offering >IMMX
Immix Biopharma Prices Public Offering of 5.5M Shares at $2.71 Each >IMMX
Immix Biopharma Prices Public Offering of 5.5M Shares at $2.71 Each >IMMX
Analysis
Price Target
No Data
